SCHEMBL659061

SCHEMBL659061

O=C(O)c1cncc(Br)c1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 5/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 2/20 0.39
AKR1C4 P17516 1/20 0.38
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
AKR1C1 Q04828 1/20 0.38
ALDH1A1 P00352 5/20 0.36
KDM4E B2RXH2 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4C Q9H3R0 2/20 0.36
KDM6B O15054 1/20 0.36
KDM4A O75164 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
KDM4D Q6B0I6 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LCK P06239 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20111331 0.88 HCAR2 (0.46) HCAR2POLBTSHRAKR1C4AKR1C3
SCHEMBL15334246 0.80 AKR1C3 (0.50) HCAR2POLBTSHRAKR1C4AKR1C3
SCHEMBL21749937 0.80 HCAR2 (0.41) HCAR2POLBTSHRAKR1C4AKR1C3
SCHEMBL4491547 0.80 SIRT3 (0.42) HCAR2POLBTSHRKDM4ETDP1
SCHEMBL3720517 0.78 HCAR2 (0.39) HCAR2POLBTSHRAKR1C4AKR1C3
SCHEMBL31450301 0.78 HCAR2 (0.39) HCAR2POLBTSHRAKR1C4AKR1C3
SCHEMBL31750197 0.78 HCAR2 (0.39) HCAR2POLBTSHRAKR1C4AKR1C3
SCHEMBL12164567 0.78 HCAR2 (0.39) HCAR2POLBTSHRAKR1C4AKR1C3
SCHEMBL16694995 0.78 HCAR2 (0.39) HCAR2POLBTSHRAKR1C4AKR1C3
SCHEMBL465860 0.78 KDM4E (0.42) HCAR2POLBAKR1C4AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250049035-A1 MICROBIOCIDAL BICYCLE HETEROCYCLIC DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2025-02-13 US disclosed
EP-4448534-A1 MICROBIOCIDAL BICYCLE HETEROCYCLIC DERIVATIVES Syngenta Crop Protection AG (CH) 2024-10-23 EP disclosed
CN-118339167-A Microbiocidal bicyclic heterocyclic derivatives 先正达农作物保护股份公司 2024-07-12 CN disclosed
WO-2023110869-A1 MICROBIOCIDAL BICYCLE HETEROCYCLIC DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2023-06-22 WO disclosed
WO-2023110869-A1 MICROBIOCIDAL BICYCLE HETEROCYCLIC DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2023-06-22 WO disclosed
EP-3227300-B1 ALDOSTERONE SYNTHASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2019-06-19 EP disclosed
EP-3227300-B1 ALDOSTERONE SYNTHASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2019-06-19 EP disclosed
US-9890171-B2 Aldosterone synthase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-02-13 US disclosed
US-9890171-B2 Aldosterone synthase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-02-13 US disclosed
EP-3227300-A1 ALDOSTERONE SYNTHASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2017-10-11 EP disclosed
WO-2016089800-A1 ALDOSTERONE SYNTHASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-06-09 WO disclosed
CN-101605794-B Azabenzofuranyl compounds and methods of use GENENTECH INC US 2013-06-12 CN disclosed
US-8378104-B2 7-aminofuropyridine derivatives OSI Pharmaceuticals, LLC (US) 2013-02-19 US disclosed
EP-2534156-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI Pharmaceuticals, LLC (US) 2012-12-19 EP disclosed
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2012-02-23 US disclosed
WO-2011100502-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI Pharmaceuticals, LLC (US) 2011-08-18 WO disclosed
CN-101605794-A Azabenzofuranyl compounds and methods of use GENENTECH INC (US) 2009-12-16 CN disclosed
US-20080085886-A1 Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide GENENTECH, INC. 2008-04-10 US disclosed
US-20080085886-A1 Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide GENENTECH, INC. 2008-04-10 US disclosed
WO-2008024725-A1 AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250049035-A1 MICROBIOCIDAL BICYCLE HETEROCYCLIC DERIVATIVES NOX1, CASP1, CYP1A1 HCAR2 609/4885POLB 1586/4885TSHR 4338/4885
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES MAP3K5, STK17A, MAPKAPK5 HCAR2 2456/4885POLB 4297/4885TSHR 4253/4885
US-20080085886-A1 Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide MAP3K2, MAP3K1, MAP2K2 HCAR2 592/4885POLB 1195/4885TSHR 3224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.